Autologous

Wilmington, Delaware, United States, July 04, 2023 (GLOBE NEWSWIRE) -- The global pericardial patches market is anticipated to grow at a 6.8% CAGR from 2023 to 2031. A market valuation of US$ 604 million is expected by the end of the…

MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months All patients were refractory to BTK…

RICHMOND, Va., June 06, 2023 (GLOBE NEWSWIRE) -- CELLF BIO achieved a major milestone with the world's first human implantation of BioSphincter™, an autologous bioengineered sphincter made of smooth muscle and differentiated neural stem…

<!-- Name:DistributionId Value:8842437 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:2791 -->…

Pune, Jan. 17, 2023 (GLOBE NEWSWIRE) -- According to Maximize Market Research, the Autologous Cell Therapy Market worth USD 26.1 Billion by 2029, growing at a 21.5% CAGR. The market is growing thanks to Government support and…

Elana Gotkine WEDNESDAY, Dec. 28, 2022 (HealthDay News) -- For patients with active secondary progressive multiple sclerosis (SPMS), autologous hematopoietic stem cell transplantation (AHSCT) is…

Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete response rate from 15 heavily pre-treated patients dosed with TT11 Research presented in an oral…

CAMBRIDGE, Mass., Dec. 10, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data from its Engineered Stem…

Portland, OR, Dec. 05, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Autologous Cell Therapy Market generated $4.3 billion in 2021, and is estimated to reach $29.1 billion by 2031,…

SINGAPORE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that three…